[市場調查報告書] 免疫調整劑：治療需求、產品線藥及未來發展趨勢

Abstract

The modulation of immune system activity is a required pharmacological intervention for many medical conditions, bearing particular importance in the treatment of autoimmune diseases and allergies and transplant procedures. With traditional immunomodulatory drugs continuing to exhibit limited efficacy and adverse side effects, the drive to develop new, improved, and specifically targeted immunotherapies has been gaining momentum. ' Immunomodulators: Therapeutic Needs, Pipelines & Prospects' is a new report published by Business Insights that provides a detailed examination of the current market for immunomodulatory therapies. The strategies and technologies used in immunomodulation are analysed and the major clinical applications of immunomodulators are reviewed to identify the leading drug classes and most promising agents currently in development. This report will also investigate patient metrics and provide market forecasts for immunomodulators to 2011.

Executive Summary

Modulating the immune system
Inflammatory and Autoimmune Disorders
Infectious disease
Cancer
Transplantation
Market Considerations and Forecasts
Trends and Opportunities

Chapter 1 Modulating the immune system

Summary
Introduction
Overview of the human immune system
Innate (non-specific) immunity
- Cytokines: the chemical messengers
- Lipid mediators of inflammation
- Phagocytic and natural killer cells
- Complement system
- Inflammatory and acute phase responses
Adaptive (specific) immunity
- B and T lymphocytes
- Antigen-presenting cells
Biopharmaceuticals as immunomodulators
Delivery of biopharmaceuticals
Regulatory requirements (US)
Scope of this Report

Chapter 2 Inflammatory and Autoimmune Disorders

Summary
Introduction
The role of T cells in autoimmune diseases and allergies
Current therapies
Glucocorticoids
Nonsteroidal anti-inflammatory drugs
Nitric oxide (NO)-releasing NSAIDs
Therapies targeting proinflammatory cytokines
B cell-targeted therapeutics
Other therapies
Current drug targets
GPCRs
- Chemokine receptors
- LTB4 receptor
- S1P1 receptor
Leukocyte surface antigens
Cytokines and their receptors
- IL-1 and receptors
- Other ILs and receptors
- TNF proteins and receptors
- BlyS (BAFF) and APRIL
- Interferons
- Other cytokines
Kinases
Other targets
Immunomodulators in clinical development (US)
Rheumatoid arthritis
Psoriasis
Multiple sclerosis
Inflammatory bowel disease
Systemic lupus erythematosus
Asthma and allergic rhinitis
Chronic obstructive pulmonary disease
Cardiovascular disease

Chapter 3 Infectious Disease

Summary
Introduction
Types of vaccines
Combination vaccines
Viruses
Influenza
- New vaccines
HIV
- New vaccines
- Other immunotherapies
Hepatitis viruses
- New vaccines
- Other immunotherapies
Herpes simplex viruses
- New vaccines
RSV
- New vaccines and immunotherapies
Bacteria, fungi and parasites
New vaccines
Other immuotherapies

Chapter 4 Cancer

Summary
Overview of Cancer
Tumor immunity
Treatment of cancer
Overview of immunotherapies
Small molecule immunomodulators
Cytokines
Monoclonal antibodies
Recent trends
Prophylactic vaccines
Therapeutic vaccines
- Tumor antigens targeted by vaccines
- Antigen/adjuvant vaccines
- Whole cell vaccines
- Dendritic cell vaccines
- Idiotype vaccines
- Genetically-engineered vaccines
Immunostimulatory sequences
Adoptive T cell immunity

Chapter 5 Transplantation

Summary
Introduction to organ transplantation
Rejection mechanisms
Prevention of rejection
Small molecule immunosuppressants
Calcineurin inhibitors
Anti-proliferatives
Glucocorticoids
mTOR inhibitors
Novel small molecule drugs
Induction therapy with T cell antibodies
Polyclonal antibodies
Monoclonal antibodies and fusion proteins
Co-stimulatory blockers
New approaches to prevention of GVHD

Chapter 6 Market Considerations and Forecasts

Summary
Introduction
Overview of the AIID Market
Rheumatoid arthritis
Multiple sclerosis
Inflammatory bowel disease
Systemic lupus erythematosus
Psoriasis
Asthma and allergic rhinitis
Overview of the Viral Infectious Disease Market
Influenza
HIV
Hepatitis viruses
Herpes simplex viruses
RSV
Overview of the Cancer Market
Cytokines
Monoclonal antibodies
Prophylactic vaccines
Therapeutic vaccines
Overview of the Transplantation Market
Quantitative Market Analysis
The global pharmaceutical market
The global immunomodulator market
Immunosuppression in AIID and allergies
Vaccines for viral pathogens
Vaccines for cancer
Monoclonal antibodies for cancer
Recombinant interferons
Transplantation medicine
Geographical analysis

Chapter 7 Trends and Opportunities

Summary
Preclinical immunomodulator programs
Trends in vaccines
Trends in monoclonal antibodies
Future players in immunomodulation
Immunomodulators Patent Survey
Patenting Activity
Leading assignees
Patent citation analysis

Appendix

Research Methodology
Index

List of Figures

Figure 7.1: Immunomodulators - Drug origins

List of Tables

Table 1.1: Immunomodulators Summary
Table 1.2: Indications by Category and Within-Category Count
Table 1.3: Recent Immunomodulator Deals
Table 2.4: Immunomodulators in US Clinical Development (Rheumatoid Arthritis)
Table 2.5: Immunomodulators in US Clinical Development (Psoriasis)
Table 2.6: Immunomodulators in US Clinical Development (Multiple Sclerosis)
Table 2.7: Immunomodulators in US Clinical Development (Crohn' s Disease)
Table 2.8: Immunomodulators in US Clinical Development (Ulcerative Colitis)
Table 2.9: Immunomodulators in US Clinical Development (SLE)
Table 2.10: Immunomodulators in US Clinical Development (Asthma)
Table 2.11: Immunomodulators in US Clinical Development (Allergic Rhinitis)
Table 2.12: Immunomodulators in US Clinical Development (COPD)
Table 2.13: Immunomodulators in US Clinical Development (General Inflammation)
Table 2.14: Immunomodulators in US Clinical Development (Autoimmune Disorders)
Table 3.15: Immunomodulators in US Clinical Development (Influenza)
Table 3.16: Immunomodulators in US Clinical Development (HIV)
Table 3.17: Immunomodulators in US Clinical Development (Viral Hepatitis)
Table 3.18: Immunomodulators in US Clinical Development (Herpes simplex)
Table 3.19: Immunomodulators in US Clinical Development (Other Viruses)
Table 3.20: Immunomodulators in US Clinical Development (Bacteria, Fungi, and Parasites)
Table 4.21: Immunomodulators in US Clinical Development (Breast cancer)
Table 4.22: Immunomodulators in US Clinical Development (Prostate cancer)
Table 4.23: Immunomodulators in US Clinical Development (Non-Small Cell Lung Cancer)
Table 4.24: Immunomodulators in US Clinical Development (Ovarian cancer)
Table 4.25: Immunomodulators in US Clinical Development (Malignant melanoma)
Table 4.26: Immunomodulators in US Clinical Development (Head and neck cancer)
Table 4.27: Immunomodulators in US Clinical Development (Pancreatic cancer)
Table 4.28: Immunomodulators in US Clinical Development (Renal cancer)
Table 4.29: Immunomodulators in US Clinical Development (Solid tumours)
Table 4.30: Immunomodulators in US Clinical Development (Lymphoma)
Table 4.31: Immunomodulators in US Clinical Development (Non-Hodgkin' s Lymphoma)
Table 4.32: Immunomodulators in US Clinical Development (Multiple myeloma)
Table 4.33: Immunomodulators in US Clinical Development (General Cancer)
Table 4.34: Immunomodulators in US Clinical Development (Colorectal cancer)
Table 4.35: Immunomodulators in US Clinical Development (Chronic Lymphocytic Leukaemia)
Table 4.36: Glossary - Immunomodulators in US Clinical Development
Table 5.37: Immunomodulators in US Clinical Development (Transplantation)
Table 6.38: World Population Data (2006)
Table 6.39: Inflammatory Disease Prevalences and Incidences (2006)
Table 6.40: Inflammatory Disease Summary (2006)
Table 6.41: World AIDS Statistics (2006)
Table 6.42: World Annual Cancer Incidence by Site (2002)
Table 6.43: Trends in cancer incidence, 1975-2000
Table 6.44: World Cancer Statistics (2002)
Table 6.45: World Pharma Market by Therapeutic Category, 2006-2011
Table 6.46: World Pharma Market by Region, 2006-2011
Table 6.47: Immunomodulator Analysis by Therapy Type (2006-2011)
Table 6.48: Immunomodulator Analysis by Indication (2006-2011)
Table 6.49: World Immunomodulator Market by Region, 2006-2011
Table 7.50: Preclinical Immunomodulators by Indication
Table 7.51: Preclinical Vaccines: Therapy Types
Table 7.52: Preclinical Vaccines: Top Indications
Table 7.53: Monoclonal antibodies in preclinical development
Table 7.54: Preclinical Immunomodulators: Top Originators
Table 7.55: Preclinical Vaccines: Top Originators
Table 7.56: Immunomodulator Patent Survey: Category Definitions
Table 7.57: Summary of Patents by Segment
Table 7.58: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (All Patents)
Table 7.59: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Autoimmunity)
Table 7.60: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Allergy)
Table 7.61: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (General Immunotherapy)
Table 7.62: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Transplantation)
Table 7.63: US Immunomodulator Patents: Filing and Publication Activity, 1992-2007 (Vaccines)
Table 7.64: US Immunomodulator Patents: Assignee Summary
Table 7.65: US Immunomodulator Patents: Top Assignees
Table 7.66: US Immunomodulator Patents: Most Frequenty Cited Organizations
Table 7.67: Top-Cited Immunomodulator Patents, Entire Data Set (US Filings, 1992-2007)